|  |  |
| --- | --- |
| **Pre-Program Assignments** | * **Pre-Lecture 1 - 2025 Viral Hepatitis Update –** A summary for discovery and natural history of viral hepatitis (25mins) * **Pre-Lecture 2 - End Stage Liver Disease**: A systematic overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process (45 mins) |
| **7:30 am** | ***Registration and View Exhibits*** |
| **8:00 am** | **Opening Comments and Pre-Test** |
| **8:25 am** | **Hepatitis C-Elimination and Care for Special Populations**   * Recap the highlights of Pre-Lecture 1 * Viral Hepatitis Elimination - Caring for At-risk populations – homeless, PWID, the incarcerated, HIV-infected individuals * Approved Direct Acting Antivirals * The vital role of specialty pharmacy * Clinical Cases and Discussion: HCV and At-Risk Individuals * Overcoming the barriers to reinfection and linkages to care. |
| **9:05 am** | **Hepatitis B: Epidemiology, Natural History, Testing and Therapies**   * Efficacies and opportunities in HBV testing and vaccination. * Disease progression and impact on liver health * The efficacy of HBV Vaccination * Anti-viral therapies of HBV * HBV Re-activation * Latest studies from EASL and AASLD |
| **9:40 am** | **Delta Hepatitis and Hepatitis E Update**   * Global and US perspective on the rapid growth of Delta Hepatitis * Bulevirtide for Delta Hepatitis * Testing and surveillance approaches * Real world outcome studies on HDV and HEV * Management of Chronic HEV |
| **10:15 am** | ***Disease Awareness Session – LAL-D, Break and View Exhibits*** |
| **11:00 am** | **End Stage Liver Disease: Recap and Clinical Cases**   * A review of Pre-course lecture on end-stage liver disease * Complications of cirrhosis * Liver transplant in the era of DAA’s * Clinical cases to illustrate HE. HRS and/or Thrombocytopenia |
| **11:30 am** | **Hepatocellular Carcinoma (HCC) - Disease Progression in the US**   * Screening diagnostic serum assays and imaging tests * Treatment and management options: Ablation, TACE and Surgery * New studies showing cost effectiveness of surveillance post SVR * PRIUS Study (MRI vs US) Abbreviated MRI * 2024 AASLD screening guidance for liver cancer. New guidelines are less critical of liver biopsy for cancer detection |
| **12:00 pm** | **Hepatocellular Carcinoma: New Systemic Treatment Options**   * **A case-based approach to HCC treatment** * Promising 1st and 2nd line therapies for liver cancer * New data on the benefit of downstaging * New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC * Checkpoint inhibitors and VEGE inhibitors |
| **12:30 pm** | ***Lunch*** |
| **1:00 pm** | ***Dessert and View Exhibits*** |
| **1:15 pm** | **Cholestatic Liver Disease: Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Pruritus**   * Epidemiology of PSC and Ursodiol and Antibiotic Treatments * Predicting outcomes and Improving Survival in PSC patients * Causes and Markers of PBC * Coping with the clinical features of PBC * Ursodeoxycholic Acid (UDCA) and Obetacholic Acid * Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar * Understanding cholestatic pruritus and helping patients cope with the itching |
| **2:10 pm** | **Alcohol Associated Liver Disease**   * The growing prevalence of alcohol over-consumption and its impact on liver health * Alcohol consumption and malnutrition * Warning signs and intervention in alcohol-associated hepatitis * Promising therapeutic agents for AAH and other alcohol associated liver disease |
| ***2:45 pm*** | ***Break and Exhibits*** |
| **3:00 pm** | **Steatotic Liver Disease: The new healthcare epidemic**   * New naming conventions for fatty liver disease: MASLD and MASH– what and why? * Epidemiology, Demographics and Diagnosis * Scoring, Staging and Management of Metabolic Liver Disease * The ‘unhealthy” rise in MASLD in the US population and What can be done * Treatment options for thrombocytopenia; including alternatives to platelet transfusion. |
| **3:40 pm** | **MASH Treatments in Practice and in Development**   * Current therapies for NASH including Updates from AASLD and EASL * Lifestyle changes as a therapy * Drugs in clinical development for NASH – Semaglutide and Resmiteron * MASH Diagnosis and Treatment case |
| **4:25 pm** | **Closing Comments, Post-test and Wrap-Up**  Program adjourns at 4:45pm |
| **Post Program Lectures:** | **Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome (**30 mins)  **Lecture 4 – AASLD Update – Highlights of the 2024 AASLD Liver Meeting (**80 mins) |

**Course Director: Paul J. Pockros, MD - Scripps Health**